<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149393</url>
  </required_header>
  <id_info>
    <org_study_id>Digestion-05</org_study_id>
    <nct_id>NCT03149393</nct_id>
  </id_info>
  <brief_title>Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules</brief_title>
  <official_title>Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiyuan Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double blind, double dummy, multicenter, parallel controlled
      clinical trial, the investigators objective is to evaluate the efficacy and safety of Qizhi
      Weitong granules in the treatment of functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double blind, double dummy, multicenter, parallel controlled
      clinical trial, the investigators objective is to evaluate the efficacy and safety of Qizhi
      Weitong granules in the treatment of functional dyspepsia. The experiment will be carried out
      in 8 sub centers at the same time, and the investigators estimated that there will be 384
      cases of income, including the experimental group and the control group (n = 192), and the
      investigators choose mosapride citrate tablets for drug control.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Main Symptom Score</measure>
    <time_frame>The score will be assessed at baseline and 2 week, 4 week, 6 week.</time_frame>
    <description>The Main Symptom Score contains evaluation of postprandial fullness discomfort, early satiety, epigastric pain, epigastric burning sensation and so on.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the Hamilton Anxiety Scale and the Hamilton Depression Scale</measure>
    <time_frame>The score will be assessed at baseline and 2 week, 4 week, 6 week.</time_frame>
    <description>To evaluate the changes of patients' mental and psychological status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Traditional Chinese Medicine</condition>
  <arm_group>
    <arm_group_label>Qizhi Weitong Granules Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will take Qizhi Weitong Granules for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosapride Citrate Tablets Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will take mosapride citrate tablets for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhi Weitong Granules</intervention_name>
    <description>Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.</description>
    <arm_group_label>Qizhi Weitong Granules Group</arm_group_label>
    <other_name>The Treatment Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride Citrate Tablets</intervention_name>
    <description>Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.</description>
    <arm_group_label>Mosapride Citrate Tablets Group</arm_group_label>
    <other_name>The Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Metting the diagnostic criteria of functional dyspepsia in Rome IV.

          2. The subjects were informed, and the subjects voluntarily signed informed consent.

          3. The subjects have reading ability.

        Exclusion Criteria:

          1. Patients suffering from gastric ulcer, gastroscopy see bleeding and mucosal erosion,
             pathological examination showed atrophy of gastric mucosa, intestinal metaplasia or
             dysplasia.

          2. Patients with Hp infection positive.

          3. Patients with gastroesophageal reflux disease.

          4. Patients with digestive system organic lesions.

          5. The patient had a history of stomach or abdominal surgery.

          6. Patients had taken the relevant drugs in the past 2 weeks.

          7. Patients suffering from severe illness affecting survival.

          8. Pregnant or lactating women.

          9. Participating in clinical trials of other drugs.

         10. Long term using of sedative hypnotics.

         11. Suspected or true alcohol, drug abuse history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tang X dong, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Xiyuan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang F yun, PhD</last_name>
    <phone>13522657731</phone>
    <phone_ext>0086</phone_ext>
    <email>wfy811@163.com</email>
  </overall_contact>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Dyspepsia</keyword>
  <keyword>Qizhi Weitong Granules</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

